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Abstract
Background: La Crosse virus (LACV), family Bunyaviridae, is a mosquito-borne virus recognized
as a major cause of pediatric encephalitis in North America with 70–130 symptomatic cases each
year. The virus was first identified as a human pathogen in 1960 after its isolation from a 4 year-old
girl who suffered encephalitis and died in La Crosse, Wisconsin. The majority of LACV infections
are mild and never reported, however, serologic studies estimate infection rates of 10–30/100,000
in endemic areas.
Results: In the present study, sequence analysis of the complete LACV genomes of low-passage
LACV/human/1960, LACV/mosquito/1978, and LACV/human/1978 strains and of biologically
cloned derivatives of each strain, indicates that circulating LACVs are genetically stable over time
and geographic distance with 99.6–100%, 98.9–100%, 97.8–99.6%, and 99.2–99.7% amino acid
identity for N, NsS, M polyprotein, and L proteins respectively. We identified 5 amino acid
differences in the RNA polymerase and 4 nucleotide differences in the non-coding region of the L
segment specific to the human virus isolates, which may result in altered disease outcomes.
Conclusion: All three wild type viruses had similar in vitro growth kinetics and phenotypes in
mosquito C6/36 and Vero cells, and similar levels of neurovirulence and neuroinvasiveness in Swiss
Webster mice. The biologically cloned derivative of LACV/human/1960 was significantly less
neuroinvasive than its uncloned parent and differed in sequence at one amino acid position in the
GN glycoprotein, identifying this residue as an attenuating mutation.
Background
La Crosse virus (LACV), family Bunyaviridae, is a mos-
quito-borne pathogen endemic in the United States.
LACV infection results in 70–130 clinical cases a year and
is the major cause of pediatric arboviral encephalitis in
North America [1-3]. LACV was first identified as human
pathogen in 1960 after its isolation from a 4 year-old girl
from Minnesota who suffered meningoencephalitis and
later died in La Crosse, Wisconsin [4,5]. The majority of
LACV infections are mild and never reported, however
serologic studies estimate annual infection rates of 10–30/
100,000 in endemic areas [2,3,6,7]. LACV is a member of
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the California serogroup of viruses in the genus Orthobun-
yavirus. The serogroup contains members found on five
continents that include human pathogens such as La
Crosse, Snowshoe hare, and Jamestown Canyon viruses in
North America; Guaroa virus in North and South Amer-
ica; Inkoo and Tahyna viruses in Europe; and Lumbo virus
in Africa [8]. Children who recover from severe La Crosse
encephalitis may have significantly lower IQ scores than
expected and a high prevalence (60% of those tested) of
attention-deficit-hyperactivity disorder [2]. Seizure disor-
ders are also common in survivors [9]. LACV can also
cause encephalitis in immunosuppressed adults [10]. Pro-
jected lifelong economic costs associated with neurologic
sequelae range from $48,775–3,090,398 per case [11]. At
present, a vaccine or FDA approved antiviral therapy is not
available.
LACV maintains an enzootic life cycle with the hardwood
forest dwelling, tree-hole mosquito, Aedes triseriatus,
which lives in the eastern half of the United States breed-
ing in tree holes and outdoor containers [12]. Ae. triseria-
tus  mosquitoes feed on Eastern gray squirrels (Sciurus
carolinensis) and Eastern chipmunks (Tamias striatus gri-
seus) which serve as amplifying hosts for LACV, and
undergo sub-clinical infections while maintaining serum
viremias high enough to infect feeding mosquitoes
[13,14]. Interestingly, the virus can be maintained in the
mosquito population in the absence of vertebrate hosts by
transovarial (vertical) transmission, thus allowing the
virus to over-winter in mosquito eggs. Mosquito infection
is lifelong and mosquitoes can become dually infected
with other bunyaviruses allowing for the development of
intra-genus reassortants [15-18].
LACV virions are pleomorphic (90–100 nm in diameter)
and have a lipid envelope containing the heteromultimer
glycoprotein [19]. The genome consists of three single-
stranded, negative-sense RNA genome segments desig-
nated small (S), medium (M), and large (L). Each genome
segment is complexed with the nucleoprotein (N) to form
three separate nucleocapsids. The termini of the 3' and 5'
non-coding regions (NCR) of each segment are comple-
mentary and highly conserved. The S segment encodes
two proteins in overlapping reading frames: the nucleo-
protein (N) and a non-structural protein (NSS). In the
related Bunyamwera virus, NSS inhibits transcription via
blocking host cell RNA polymerase II which decreases
overall host cell protein synthesis in mammalian cells
including a decrease in both the induction of interferon
and its signaling in infected cells [20,21]. Recombinant
LACV virions lacking the NSS gene are viable, indicating
that the NSS is a nonessential accessory protein [22]. The
M segment encodes a single polyprotein (M polyprotein)
that is post-translationally processed into two glycopro-
teins (GN and GC) that form a heteromultimer in the vir-
ion and a non-structural protein (NSM) of unknown
function [23]. The L segment encodes a single open read-
ing frame for the RNA dependent RNA polymerase (L)
[24,25]. The L polymerase uses host-cell 5' mRNA
sequences, including the cap structures, to prime its own
mRNA synthesis, a process that also contributes to the
observed shut-off of host cell protein synthesis following
infection.
To identify a nucleotide sequence of LACV associated with
the wild type phenotype, i.e. replication competent in
insect and mammalian cells and able to cause encepha-
litic disease in suckling and weanling mice by a peripheral
and intracerebral route of inoculation, we sequenced the
complete genomes of three low-passage LACV isolates,
namely, LACV/human/1960, LACV/human/1978, LACV/
mosquito/1978, isolated over a 18 year period of time.
Biologically cloned derivatives of each virus were also
sequenced. The level of neurovirulence and neuroinva-
siveness for each of the three virus isolates and their
cloned derivatives was determined in mice by assessing
clinical disease following intracerebral or intraperitoneal
administration of virus. LACV strains appear highly genet-
ically stable in nature, grow to high titers in monkey and
mosquito cell cultures, and are highly neurovirulent and
neruoinvasive for mice even at low dosage. Since one of
the long-term goals of this project is to develop a live
attenuated virus vaccine for LACV, the identification of a
nucleotide sequence of LACV that specifies a wild type
phenotype was seen as an essential first step in this proc-
ess. In this study, we have also identified a single amino
acid substitution in GN in one of the cloned LACV strains
that greatly decreases LACV neuroinvasiveness. Such a
mutation may be useful in developing live-attenuated
virus vaccine candidates.
Results
Sequence analysis of viral genomes
LACV genomes were sequenced for two reasons. First, we
wanted to determine the genetic diversity of LACV iso-
lated in different regions of the United States at different
times, and second, we sought to define a complete
genomic sequence that is associated with the wild type
phenotype of virulence in mice by both peripheral and
intracerebral routes of inoculation. The sequence of only
two complete LACV genomes was previously reported,
one human isolate (LACV/human/1978, GenBank acces-
sion numbers NC_004108–NC_004110) and one mos-
quito isolate (strain 77, LACV/mosquito/1977, GenBank
accession numbers DQ196118–DQ196120) (Table 1).
We sequenced two additional isolates, including the orig-
inal La Crosse, Wisconsin virus (LACV/human/1960) and
the LACV/mosquito/1978 virus (Table 1), and re-
sequenced LACV/human/1978 after an additional pas-
sage in tissue culture to confirm its identity prior to furtherVirology Journal 2007, 4:41 http://www.virologyj.com/content/4/1/41
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biological characterization. In addition, LACV/human/
1960, LACV/mosquito/1978, and LACV/human/1978
parental wild-type viruses were biologically cloned to gen-
erate a genetically homogeneous viral preparation, and
the full sequence of these cloned preparations was also
determined. Thus, we have generated full-length sequence
for 3 pairs of cloned and uncloned LACV strains. For
LACV/human/1978, the newly derived sequence
(EF485033-35) was used for all subsequent comparisons
since several differences with the former sequence were
identified. An examination of the virulence phenotype of
these three parental and cloned viruses in mice should
define one or more full-length sequences that have a wild
type phenotype.
A comparison of the complete genomic nucleotide
sequences from low passage LACV isolates of either
human or mosquito origin isolated over an 18 year period
of time from two geographically different regions of the
United States (Table 2) indicated little sequence diver-
gence. The S, M, and L genome segments for each virus
were 984, 4526, and 6980 nucleotides in length, respec-
tively. The nucleotide length of the segments and the
encoded open reading frames for each of the isolates are
identical. The S, M, and L segments from each virus isolate
share a high nucleotide sequence identity ranging from
97.9–100%, 95.7–99.8%, and 95.7–99.4% respectively
(Table 2). The N, NSs, M polyprotein, and L protein open
reading frames are 235, 92, 1441, and 2263 amino acid
codons in length, respectively. The percent identity for
encoded proteins is also highly conserved among the iso-
lates with 99.6–100%, 98.9–100%, 97.8–99.6%, and
99.2–99.7% identity for the N, NSs, M polyprotein, and L
proteins, respectively (Table 2). Although the process of
biological cloning resulted in an additional four passages
in Vero cells, these passages had a minimal effect on
genetic stability. A maximum of four nucleotide changes
were observed between a wild type parental virus stock
and its biologically cloned derivative, and no more then
one amino acid change was observed in any cloned virus
(Table 3). This level of sequence divergence between
parental and cloned virus is much less than that between
LACV isolates (> 500 nucleotides differences for human/
1978 compared to mosquito/1978), clearly identifying
each isolate as a separate strain.
The sequences of two LACV isolates from humans were
compared with two isolates from mosquitoes to identify
amino acids that are shared by LACVs of human origin
but that differ from LACVs of mosquito origin. Such
sequences differences are referred to as host-specific
sequence substitutions. Five such host-specific amino acid
substitutions were identified, and all were located in the L
protein (Table 4). Four nucleotide substitutions in the
non-coding region (NCR) of the L segment at nucleotides
31, 6876, 6877, and 6921 also appear to be host-specific
(Figure 1 and 2).
The 3' and 5' genome ends of the LACV genomes were also
highly conserved. The first 11 and last 11 nucleotides were
identical for each segment end (Figure 1 and 2). Each 3'
NCR was identical for the S (nt 1–81) and only one nucle-
otide differed from the consensus in the M (nt 1–61) seg-
ments. The 3' NCR of L (nt 1–61) from LACV/mosquito/
1978 differed from the consensus by 2 nucleotides (Figure
1). The 5' NCR of LACV/mosquito/1978 differed from the
S, M, and L consensus by 8, 3, and 1 nucleotides, respec-
tively. For the L segment, a clear consensus sequence was
not identified at position 31 of the 3' end and at nucle-
otide positions 6876, 6877, 6888, and 6921 in the 5'
NCR. Between the two human isolates, one nucleotide
difference in the NCR was identified at position 6888 of
the 5' NCR of L (Figure 2).
Table 1: Passage history and geographic location of isolation/infection of the LACV isolates for which complete genomic sequences are 
available.
Virus Location Passage historya GenBank Accession number
LACV/human/1960 Minnesota C6/36 2 EF485030–EF485032
LACV/human/1960-clone Minnesota C6/36 2, Vero 4 NAb
LACV/mosquito/1978 North Carolina Mouse brain 1, Vero 3 EF485036–EF485038
LACV/mosquito/1978-clone North Carolina Mouse brain 1, Vero 7 NA
LACV/human/1978 Wisconsin Mouse brain 1, BHK 2, Vero 1 EF485033–EF485035
LACV/human/1978-clone Wisconsin Mouse brain 1, BHK 2, Vero 5 NA
LACV/mosquito/1977 Wisconsin Unknown DQ196118–DQ196120c
LACV/human/1978 Wisconsin Mouse brain 1, BHK 2 NC_004108–NC_004110d
aCell/tissue type followed by number of passages.
bSequence not submitted. Genetic comparisons with uncloned parental wild-type stocks found in Table 3.
cPrevious submission by Cheng et al. 2005.
dPrevious submission by Hughes et al. 2002. Sequence from a derivative of this virus (one additional passage in Vero cells) was generated for this 
study (EF485033–EF485035) and used for subsequent comparisons since several differences with this sequence were identified.Virology Journal 2007, 4:41 http://www.virologyj.com/content/4/1/41
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In vitro growth kinetics
Comparison of in vitro growth of LACV/human/1960,
LACV/mosquito/1978 and LACV/human/1978 viruses
was performed in Vero cells and C6/36 cells (Figure 3). All
viruses replicated to high titers in both cell types. LACV/
human/1960 replicated more quickly in C6/36 cells, pos-
sibly as a result of originally being isolated in these cells.
Growth kinetics in Vero cells for all three viruses were
nearly identical reaching approximately 107 PFU/ml in 24
hours (Figure 3A). Each of the three viruses replicated effi-
ciently in C6/36 cells, but, in contrast to the rapid devel-
opment of cytopathic effects (CPE) in Vero cells, infection
Table 3: Nucleotide differences between wild type parental and biologically cloned virus.
LACV Virus Nucleotide substitution in indicated LACV segmenta
SML
human/1960-clone A525T A503Gb A1837G
C2221T
human/1978-clone No changesc T391C No changes
A1636G
A1929Gb
mosquito/1978-clone A719Gb No changes A31G
G33A
aParental nucleotide on left, nucleotide substitution in the cloned virus on right.
bIndicates a nucleotide substitution resulting in an amino acid substitution.
cParental and cloned virus have identical sequences.
Table 2: Nucleotide and amino acid identity (%) of the LACV genomic segments and their predicted protein products.
Human/1960 Human/1978 Mosquito/1978 Mosquito/1977
S segment/N 
protein
Human/1960 - 99.6 100 100 Amino Acid
Human/1978 99.8 - 99.6 99.6
Mosquito/1978 98.1 97.9 - 100
Mosquito/1977 Nucleotide 100 99.8 98.1 -
S segment/NSs 
protein
Human/1960 - 98.9 100 100 Amino acid
Human/1978 99.8 - 98.9 98.9
Mosquito/1978 98.1 97.9 - 100
Mosquito/1977 Nucleotide 100 99.8 98.1 -
M segment/M 
polyprotein
Human/1960 - 99.4 97.8 99.6 Amino acid
Human/1978 99.6 - 97.8 99.4
Mosquito/1978 95.8 95.8 - 97.7
Mosquito/1977 Nucleotide 99.8 99.5 95.7 -
L segment/L 
protein
Human/1960 - 99.7 99.2 99.5 Amino acid
Human/1978 99.4 - 99.2 99.5
Mosquito/1978 95.9 95.7 - 99.5
Mosquito/1977 Nucleotide 97.1 96.9 96.0 -Virology Journal 2007, 4:41 http://www.virologyj.com/content/4/1/41
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of C6/36 cells was not cytopathic over the seven day
period (data not shown). CPE associated with LACV infec-
tion of Vero cells consisted of cell rounding and detach-
ment from the flask with 80% of the monolayer destroyed
by 3 days post-infection (Figure 3B).
LACV clinical disease in mice: LD50
All six LACV isolates were neurovirulent in Swiss Webster
mice regardless of previous passage in mouse brains. In
suckling or weanling mice, the LD50 values ranged from -
0.50 to 1.50 log10 PFU (Table 5). Thus, each of the three
genome sequences of the parental and cloned viruses is a
sequence of a fully neurovirulent virus. Of the six LACV
isolates tested, five were neuroinvasive for mice of both
ages whereas the LACV/human/1960-clone did not
induce clinical disease in weanling mice even after inocu-
lation of 106 PFU (Table 5). It was determined that this
virus has a nucleotide substitution (A503G) resulting in a
single amino acid change at position 148 (Thre-
onine→Alanine) in the GN  (formerly G2) attachment
glycoprotein and three silent nucleotide substitutions
(Table 3). This suggests that the alanine residue at posi-
tion 148 attenuates neuroinvasiveness. Clinical disease in
mice included lethargy, tremors, seizures, and limb paral-
ysis, although there was no consistent sequence to the
progression of disease.
Discussion
As an initial step in vaccine development, we defined a
panel of LACV genomic sequences that is associated with
Alignment of 3' non-coding region of S, M, and L genome segments (cDNA presented) Figure 1
Alignment of 3' non-coding region of S, M, and L genome segments (cDNA presented). S segment 3' NCR shows 
highly conserved sequence with no nucleotide changes from the consensus. For each segment the consensus sequence consists 
of three or more sequences sharing the same nucleotide at a given position and areas with no clear consensus are indicated 
with an "N". A single nucleotide change was reported in the LACV/mosquito/1977 published sequence at position 9 of the M 
segment. For the 3' NCR of the L segment, 2 changes from the consensus were observed in LACV/mosquito/1978 with posi-
tion 31 having no clear consensus. Underlined sequence indicates region conserved among all three segments. Putative host-
specific nucleotide sequences are indicated with an arrow (↓).
     S segment 3’ non-coding region (nt 1-81).
                          1                                                                              81 
   LACV/human/1960     3’ ................................................................................. 5’ 
   LACV/human/1978     3’ ................................................................................. 5’ 
   LACV/mosquito/1978  3’ ................................................................................. 5’ 
   LACV/mosquito/1977  3’ ................................................................................. 5’ 
   Consensus           3’ AGTAGTGTACTCCACTTGAATACTTTGAAAATAAATTGTTGTTGACTGTTTTTTACCTAAGGGGAAATTATCAAGAGTGTG 5’ 
    M segment 3’ non-coding region (nt 1-61).
                          1                                                          61 
   LACV/human/1960     3’ ............................................................. 5’ 
   LACV/human/1978     3’ ............................................................. 5’ 
   LACV/mosquito/1978  3’ ............................................................. 5’ 
   LACV/mosquito/1977  3’ ........G.................................................... 5’ 
   Consensus           3’ AGTAGTGTACTACCAAGTATAGATAACGTTTGAATATTAAAGTTTTGAATCAAAGCCAAAG 5’ 
    L segment 3’ non-coding region (nt 1-61).
                          1 p                            61 
   LACV/human/1960     3’ ..............................G.............................. 5’ 
   LACV/human/1978     3’ ..............................G.............................. 5’ 
   LACV/mosquito/1978  3’ ..............................A.G......................C..... 5’ 
   LACV/mosquito/1977  3’ ..............................A.............................. 5’
   Consensus           3’ AGTAGTGTACTCCTATCTACAAAACTTACANAAAATTCAGTCATATCACAATATATGCATA 5’ 
Table 4: Host specific amino acid differences are located in the RNA polymerase (L).
Amino acid position Amino acid residue
Human Mosquito
129 V I
484 K R
1040 E G
1713 T A
1906 A S
Genetic comparisons used all wild-type parental sequences generated for this paper and published sequences of mosquito strain LACV-77 
(DQ196118–DQ196120). RNA polymerase amino acid 922 was R or G in the human isolates and K in the two mosquito isolates.Virology Journal 2007, 4:41 http://www.virologyj.com/content/4/1/41
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wild type in vitro and in vivo phenotypes. This was done by
examining the phenotypic properties of parental and bio-
logically cloned derivatives of three LACV viruses. For our
purpose, a LACV was defined as exhibiting a wild type
phenotype if it was fully replication competent in insect
and mammalian cells and was able to cause encephalitic
disease in suckling and weanling mice by a peripheral and
intracerebral route of inoculation. Although LACV does
not appear virulent in either mosquitoes or in its amplify-
ing hosts in nature, it is clearly virulent in humans and
mice resulting in severe central nervous system (CNS)
infections in both species. Therefore, this virulence for
CNS of mice is the phenotype that we would like to mod-
ify as a surrogate phenotype for the development of a
attenuated vaccine candidates for humans. Five of the six
LACV isolates studied, three parental and two cloned
viruses, had the wild type virulence phenotype in vivo.
These defined wild type sequences can now be used as a
baseline for the identification of mutations that attenuate
LACV for the CNS. A live, attenuated LACV virus vaccine
could reduce the occurrence of LACV encephalitis in the
U.S., and possibly could be useful as a genetic background
for the creation of chimeric vaccines against other patho-
gens in the Bunyaviridae family as has been successfully
done for the flaviviruses and paramyxoviruses [26,27].
In the present study, the complete genomic sequence of
two wild type LACV isolates was determined, and one pre-
viously determined sequence was confirmed with some
minor clarifications of the published sequences. These
three LACV sequences, along with a previously deter-
mined sequence, were compared to examine the extent of
genetic diversity of the LACV genome. Although these
four viruses originated in distinct geographic locations
and were isolated from either humans or mosquitoes over
a period of 18 years, the viruses exhibited a remarkable
Alignment of 5' non-coding region of S, M, and L genome segments (cDNA presented) Figure 2
Alignment of 5' non-coding region of S, M, and L genome segments (cDNA presented). Among the two human 
isolates only one nucleotide difference was observed in the NCR of the L segment at position 6888. For each segment, the 
consensus sequence consists of three or more sequences sharing the same nucleotide at a given position and areas with no 
clear consensus are indicated with and "N". Underlined sequence indicates region conserved among all three segments. Puta-
tive host-specific nucleotide sequences are indicated with an arrow (↓).
S segment 5’ non-coding region (nt 787-984). 
                          787                                                                                              887 
    LACV/human/1960    3’ .................................................................................................... 5’ 
    LACV/human/1978    3’ .................................................................................................... 5’
    LACV/mosquito/1978 3’ ......G.............AG...C.............C.......C......T....................T........................ 5’
    LACV/mosquito/1977 3’ .................................................................................................... 5’
    Consensus          3’ TAAATATGGCATGAGGCATTCAAATTAGGTTCTAAATTCTAAATTTATATATGTCAATTTGATTAATTGGTTATCCAAAAGGGTTTTCTTAAGGGAACCC 5’
                          888                                                                                            984 
    LACV/human/1960    3’ .................................................................................................. 5’ 
    LACV/human/1978    3’ .................................................................................................. 5’
    LACV/mosquito/1978 3’ .................................................................................................. 5’
    LACV/mosquito/1977 3’ .................................................................................................. 5’
    Consensus          3’ ACAAAAATAGCAGCTAAATGGGTGGGTGGTAGGGGACAGCAAAAAACTATAAATCAGGTCATAAATAAAATAAAATGTATTCAGTGGAGCACACTACT 5’ 
 M segment 5’ non-coding region (nt 4385-4526). 
                          4385                                                                                            4485
    LACV/human/1960    3’ .................................................................................................... 5’
    LACV/human/1978    3’ .................................................................................................... 5’
    LACV/mosquito/1978 3’ .....A............T...................................C............................................. 5’
    LACV/mosquito/1977 3’ .................................................................................................... 5’
    Consensus          3’ TAGGGGATCTATGCAGAACAAAATTGAGTCCTGTATTATATATTCTATTTGTAGTATAGCTGTTGTTAAGTGGGGGGTGGGGAACTAACAACAGCGTAAA 5’
                          4486                                  4526 
    LACV/human/1960    3’ .......................................... 5’ 
    LACV/human/1978    3’ .......................................... 5’ 
    LACV/mosquito/1978 3’ .......................................... 5’ 
    LACV/mosquito/1978 3’ .......................................... 5’
    Consensus          3’ TTTATTTTGCAAACATTATTTTATACTTGGTAGCACACTACT 5’ 
 L segment 5’ non-coding region (nt 6851-6980). 
                          6851 pp                                           p                         6950 
    LACV/human/1960    3’ .........................CT..........C................................A............................. 5’ 
    LACV/human/1978    3’ .........................CT..........T................................A............................. 5’
    LACV/mosquito/1978 3’ .........................TG..........T................................G............................. 5’
    LACV/mosquito/1977 3’ ..........A..............TG..........C................................G............................. 5’
Consensus          3’ TAGTAGTTATGAGTTTACAGAGAACNNACAATTAGGCNATAAATTTGGGAGGGTTTTGGAAATTGGCTAANATTCAAAAAGAGGGGGATTAACAGCAACT 5’ 
                           6951                      6980 
    LACV/human/1960    3’ .............................. 5’ 
    LACV/human/1978    3’ .............................. 5’ 
    LACV/mosquito/1978 3’ .............................. 5’ 
    LACV/mosquito/1977 3’ .............................. 5’ 
    Consensus          3’ GTATAAATTTGTAGATAGGAGCACACTACT 5’Virology Journal 2007, 4:41 http://www.virologyj.com/content/4/1/41
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level of genetic relatedness independent of passage his-
tory, location of isolation, or host. The N open reading
frame of the S segment was the most conserved protein
sequence (≥ 98% identity) among the isolates, followed
by that of the RNA polymerase L, NSs, and M polyprotein
(≥ 95% identity). It is possible that ecological factors, such
as the need to replicate efficiently in both mammalian
and insect hosts, have selected for a genotype that has
obtained maximum fitness in both hosts. In such a
model, variants that arise by genetic drift may be quickly
selected against by either host. Clearly, a greater number
of isolates from both hosts still need to be examined, but
recovery of LACV from humans is unusual and isolates are
rare.
Since we had complete sequences for two viruses isolated
from mosquitoes and two from humans, it was possible
to search for host specific sequences that distinguish
between LACV isolates obtained from the two species.
Five amino acid substitutions were found in the RNA
polymerase and may define the host-specific genetic dif-
ferences. In addition, four nucleotide differences in the
NCR of the L segment also appear to be host-specific. Such
host-specific differences were not identified in the S or M
segments. None of the differences is located in the con-
served Bunaviridae L protein motifs A-D [28]. Since the
human isolates would only be obtained from sympto-
matic cases, it is possible that the L segment of the LACV
might be a determinant of virulence in humans and that
only those LACVs with a specific L segment sequence are
isolated from humans with disease. Since there were nine
host-specific differences between the human and mos-
quito isolates, it is unlikely, although not impossible, that
nine shared changes would have co-developed during the
replication of a LACV in two different humans following
infection with the mosquito genotype. Rather, it is likely
that there are subsets of LACV strains in nature, only some
of which might be capable of causing severe disease in
humans. Since virus with mosquito- or human-specific L
segment sequences did not differ in virulence in mice, this
Growth kinetics and CPE of LACV strains Figure 3
Growth kinetics and CPE of LACV strains. A. Growth kinetics of LACV/human/1960, LACV/human/1978, and LACV/
mosquito/1978 in Vero cells or C6/36 cells infected at an MOI of 0.01. B. Photographs of mock or LACV/human/1960 infected 
Vero cell monolayers from panel "A". Cell rounding and detachment from the flask can be seen on days 2–4 post-infection in 
infected monolayers.
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suggestion of an association of a sequence with human
disease is offered with great caution. As additional virus
isolates from humans become available for sequence
analysis, it will be important to monitor these specific
amino acids and nucleotides for their association with
human disease. In addition, it will be interesting to deter-
mine if viruses with the human host specific sequences
can be directly isolated from mosquitoes.
As a first step towards vaccine development, we sought to
establish a reproducible murine model of LACV infection
suitable for pathogenesis and vaccine safety/efficacy stud-
ies. In humans, disease incidence is age dependent with
the majority of cases in children under 15 years old[13].
Previous studies in BALB/C mice using LACV/human/
1960, passaged nine times in suckling mouse brain and
two times in BHK cells, resulted in an age-specific decrease
in neuroinvasiveness most notable at 3 weeks of age [29].
In our Swiss Webster mouse model, the LD50 values were
similar for both age groups, with the exception of the bio-
logically cloned LACV/human/1960. This virus was neu-
roinvasive in suckling mice but not in weanling mice
presumably due to a mutation in the GN glycoprotein.
Although the GN glycoprotein is believed to play a role in
binding of LACV virions to mosquito midgets, it may also
have a role in the development of CNS disease[30]. Future
work will focus on understanding which step in disease
progression is blocked after infection with a virus bearing
this mutation in GN. The use of 3-week-old weanling mice
was advantageous because they are more mobile than
suckling mice allowing for a more detailed observation of
clinical disease manifestations. Following inoculation of
5-week-old Swiss Webster mice with 105 PFU of LACV/
mosquito/1978 (a dose 100% lethal for 3-week-old mice)
only 50% (3 of 6) became ill (data not shown), suggesting
that Swiss Webster mice will also be useful in understand-
ing age-dependent neuroinvasiveness of LACV.
Conclusion
Taken together, these results have implications for our
future vaccine development efforts. First, LACV is geneti-
cally stable over time and distance, suggesting that a vac-
cine based on any of these virus isolates should induce a
protective immune response against most, if not all, circu-
lating LACV strains. Second, we have identified a muta-
tion in the GN glycoprotein that appears to be associated
with decreased neuroinvasiveness, yet does not affect
virus replication in tissue culture. Clearly, our current in
vivo  testing allows for the identification of mutations
effecting neuroinvasiveness. Third, we have identified a
convenient mouse model that will allow us to screen
numerous mutant viruses for attenuated neuroinvasive-
ness/neurovirulence and allow us to continue to evaluate
the pathogenesis of LACV infection and disease.
Methods
Cells and viruses
C6/36 cells (Aedes albopictus mosquito larvae) were main-
tained in Earle's MEM supplemented with 10% fetal
bovine serum (HyClone), 2 mM L-glutamine (Invitro-
gen), and 1 mM non-essential amino acids. Vero cells
(African green monkey kidney) were maintained in Opti-
PRO™ SFM medium (Invitrogen) supplemented with 4
mM L-glutamine (Invitrogen).
LACV/human/1960 was isolated from post-mortem brain
tissue collected from a Minnesota patient hospitalized in
La Crosse, Wisconsin and passaged two times in C6/36
cells. LACV/mosquito/1978 was isolated from mosqui-
toes collected in North Carolina and passaged once in
mouse brain and three times in Vero cells. LACV/human/
1978 was isolated from post-mortem brain tissue col-
lected in Wisconsin and passaged once in mouse brain,
twice in BHK-21 cells, and once in Vero cells (Table 1).
Table 5: La Crosse neurovirulence and neuroinvasiveness after intracerebral (IC) or intraperitoneal (IP) inoculation of Swiss Webster 
mice.
Virus Neurovirulence (IC)
(LD50 log10 PFU)
Neuroinvasiveness (IP)
(LD50 log10 PFU)
Suckling micea Weanling miceb Suckling mice Weanling mice
LACV/human/1960 1.35 1.30 2.17 2.56
LACV/human/1960-clonec 1.37 -0.25 1.76 > 6.0
LACV/human/1978 0.37 -0.50 0.57 1.75
LACV/human1978-clone 0.42 -0.15 0.83 1.25
LACV/mosquito/1978 1.19 1.13 1.08 1.84
LACV/mosquito/1978-
clone
1.36 1.50 1.29 2.40
aSuckling mice are 2–3 days old.
bWeanling mice are 21–23 days old.
cBiologically cloned viruses were obtained by terminally diluting wild type parental virus three times, then amplified by an additional passage in tissue 
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Isolation of biologically cloned viruses
Biological clones were generated by terminal dilution in
Vero cell cultures. Virus stocks were serially diluted in 2-
fold increments and inoculated onto 90% confluent mon-
olayers of Vero cells in 96-well plates using eight wells per
dilution. After five days of incubation, cell culture fluid
was removed to a holding plate, and the cell monolayers
were fixed and stained for 10 minutes with crystal violet
solution (1% crystal violet in equal volumes of ethanol
and methanol). The virus was selected as a clonal deriva-
tive when only 1 or 2 of the 8 wells in a single row was
positive for LACV CPE. Each virus was terminally diluted
three times (sequentially), amplified in Vero cell culture,
and subjected to genome sequence analysis.
Virus titrations
Vero cells in 24-well plates were infected in duplicate with
ten-fold serial dilutions of LACV and overlayed with Opti-
MEM (Invitrogen) supplemented with 1% methylcellu-
lose, 5% FBS, 2.5 μg/ml amphotericin B, and 20 μg/ml
ciprofloxicin. Five days after infection the overlay was
removed and cells were washed twice with PBS. The cells
were fixed and stained for 10 minutes with crystal violet
solution, viral plaques were identified by characteristic
CPE, and titers are expressed as log10 PFU/ml.
Sequence analysis of viral genomes
Viral RNA was isolated using either QIAamp Viral RNA kit
(Qiagen) or EZ1 Viral RNA mini kit (Qiagen). Reverse
transcription (RT) was performed using random hexamer
primers and SuperScript™ First-Strand Synthesis System
for RT-PCR (Invitrogen). Overlapping PCR fragments
were generated using LACV specific primers and Advan-
tage cDNA polymerase reaction kit (BD Biosciences Clon-
tech). PCR fragments of up to 2000 bp were purified and
both strands directly sequenced using viral specific prim-
ers in BigDye-terminator cycle sequencing reactions ana-
lyzed on an ABI3730 genetic analyzer (Applied
Biosystems). Sequence fragments were assembled into a
consensus sequence using AutoAssembler 2.1 software
(Applied Biosystems).
To sequence the 5' and 3' genome ends, viral RNA was iso-
lated using QIAamp Viral RNA kit (Qiagen) from virus
infected cells at 24–48 hours post infection for the 3' non-
coding region (NCR) or from cell culture supernatant
fluid for the 5' NCR. Viral RNA was reverse transcribed
using Reverse Transcriptor (Roche) at 55°C with random
hexamer primers for the 3' NCR or at 60–70°C with
genome specific primers that enhanced reverse transcrip-
tion though RNA secondary structures. cDNA was purified
with High Pure (Roche) and a poly-A tail was added to the
3' end of the cDNA using 5'/3' RACE Kit, Second Genera-
tion (Roche). Genome ends were then amplified using
virus and poly-A specific primers. Purified PCR fragments
were sequenced as described above.
In vitro growth kinetics
LACV/human/1960, LACV/mosquito/1978, and LACV/
human/1978 were used to infect 95% confluent monol-
ayers of C6/36 or Vero cells at a multiplicity of infection
of 0.01 and incubated for one hour to allow attachment.
Infected monolayers were washed twice with sterile PBS
and overlaid with medium. Tissue culture fluid (0.5 ml)
was collected every 24 hours after infection, mixed 1:10
with 10× SPG buffer (final concentration 218 mM
sucrose, 6 mM L-glutamic acid, 3.8 mM dibasic potassium
phosphate, pH 7.2), and frozen. Daily samples were
titrated as described above. Cell monolayers were photo-
graphed on day 0, 1, 2, 3, and 4 for LACV/human/1960
infected, or non-infected Vero cells.
LACV clinical disease in mice
The lethal dose50 (LD50) of LACV virus was evaluated in
Swiss Webster suckling and weanling mice (Taconic
Farms, Germantown, NY). All animal experiments were
carried out in accordance with the regulations and guide-
lines of the National Institutes of Health. Litters of 3 day-
old suckling mice (n > 8/dose) were inoculated with serial
dilutions of wild type or biologically-cloned LACV in a
volume of 10 μl intracerebrally (IC) or 100 μl intraperito-
neally (IP). The experiment was repeated with 3 week-old
weanling mice (n = 6/dose), however, the older mice were
anesthetized with isofluorane prior to IC inoculation. All
mice were carefully observed twice daily for clinical dis-
ease including tremors and limb paralysis. Because clini-
cally moribund mice were humanely euthanized before
succumbing to infection, moribundity served as a surro-
gate for the determination of lethality.
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